Suppr超能文献

饮食干预改变造血干细胞移植患者肠道微生物代谢的可行性。

Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation.

机构信息

Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA.

Department of Internal Medicine, Division of Infectious Disease, University of Michigan, Ann Arbor, MI, USA.

出版信息

Nat Med. 2023 Nov;29(11):2805-2813. doi: 10.1038/s41591-023-02587-y. Epub 2023 Oct 19.

Abstract

Evaluation of the impact of dietary intervention on gastrointestinal microbiota and metabolites after allogeneic hematopoietic stem cell transplantation (HCT) is lacking. We conducted a feasibility study as the first of a two-phase trial. Ten adults received resistant potato starch (RPS) daily from day -7 to day 100. The primary objective was to test the feasibility of RPS and its effect on intestinal microbiome and metabolites, including the short-chain fatty acid butyrate. Feasibility met the preset goal of 60% or more, adhering to 70% or more doses; fecal butyrate levels were significantly higher when participants were on RPS than when they were not (P < 0.0001). An exploratory objective was to evaluate plasma metabolites. We observed longitudinal changes in plasma metabolites compared to baseline, which were independent of RPS (P < 0.0001). However, in recipients of RPS, the dominant plasma metabolites were more stable compared to historical controls with significant difference at engraftment (P < 0.05). These results indicate that RPS in recipients of allogeneic HCT is feasible; in this study, it was associated with significant alterations in intestinal and plasma metabolites. A phase 2 trial examining the effect of RPS on graft-versus-host disease in recipients of allogeneic HCT is underway. ClinicalTrials.gov registration: NCT02763033 .

摘要

异体造血干细胞移植(HCT)后饮食干预对胃肠道微生物群和代谢物的影响评估不足。我们进行了一项可行性研究,作为两阶段试验的第一阶段。10 名成年人从第-7 天到第 100 天每天接受抗性马铃薯淀粉(RPS)。主要目的是测试 RPS 的可行性及其对肠道微生物群和代谢物的影响,包括短链脂肪酸丁酸。可行性达到了设定的 60%或更高的目标,坚持 70%或更高的剂量;当参与者服用 RPS 时,粪便丁酸水平明显高于不服用时(P < 0.0001)。一个探索性目标是评估血浆代谢物。与基线相比,我们观察到了与 RPS 无关的血浆代谢物的纵向变化(P < 0.0001)。然而,在接受 RPS 的受者中,与历史对照相比,其主要的血浆代谢物更稳定,在植入时具有显著差异(P < 0.05)。这些结果表明,异体 HCT 受者的 RPS 是可行的;在这项研究中,它与肠道和血浆代谢物的显著改变有关。一项正在进行的研究检查了 RPS 对异体 HCT 受者移植物抗宿主病的影响。ClinicalTrials.gov 注册号:NCT02763033。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0081/10667101/61330f142988/41591_2023_2587_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验